Advanced non-small cell lung cancer chemotherapy: a randomized trial of two active regimens (MVP and PE)

The treatment of advanced or metastatic NSCLC remains a controversial issue and cisplatin-based combination chemotherapy is by far the most common treatment. Two of these cisplatin-based standard combinations, MVP and PE, were compared in this study in order to evaluate their response rates and surv...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer letters Vol. 119; no. 2; pp. 241 - 247
Main Authors:	Ginopoulos, P., Spyropoulos, K., Kardamakis, D., Dougenis, D., Onyenadum, A., Gogos, C.H., Solomou, E., Chrysanthopoulos, K.
Format:	Journal Article
Language:	English
Published:	Shannon Elsevier Ireland Ltd 11-11-1997 Elsevier
Subjects:	Adult Advanced non-small cell lung cancer Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Cisplatin Cisplatin - administration & dosage Cisplatin - adverse effects Double-Blind Method Etoposide Etoposide - administration & dosage Etoposide - adverse effects Female Humans Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Mitomycin Mitomycin - administration & dosage Mitomycin - adverse effects Pharmacology. Drug treatments Treatment Outcome Vindesine Vindesine - administration & dosage Vindesine - adverse effects Etoposide Advanced non-small cell lung cancer Mitomycin Vindesine Cisplatin Antineoplastic agent Lung disease Respiratory disease Toxicity Treatment efficiency Tolerance Malignant tumor Bronchopulmonary Podophyllotoxine derivatives Alkaloid Chemotherapy Treatment Secondary effect Bronchus disease Clinical trial Advanced stage Non small cell carcinoma Platinum II Complexes
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The treatment of advanced or metastatic NSCLC remains a controversial issue and cisplatin-based combination chemotherapy is by far the most common treatment. Two of these cisplatin-based standard combinations, MVP and PE, were compared in this study in order to evaluate their response rates and survival times. Eighty-five previously untreated NSCLC patients were randomly selected to receive either MVP or PE and 72 of these patients were eligible for evaluation for response rate and survival. Response rates for MVP were: CR 11%, PR 35%, SD 19% and PD 35% and for PE: CR 0%, PR 26%. SD 22% and PD 52%. The median survival time was 9.7 months for MVP and 6.9 months for PE. Both schedules were well tolerated. The administration of MVP in advanced NSCLC resulted in superior response rates and survival times over those produced by PE.
ISSN:	0304-3835 1872-7980
DOI:	10.1016/S0304-3835(97)00301-7